Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.
Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:
(12) Patent: | (11) CA 1214725 |
---|---|
(21) Application Number: | 1214725 |
(54) English Title: | CONTRACEPTIVE VAGINAL TABLETS AND PROCESS FOR PREPARING THEM |
(54) French Title: | COMPRIMES VAGINAUX CONTRACEPTIFS ET METHODE DE PREPARATION |
Status: | Term Expired - Post Grant |
(51) International Patent Classification (IPC): |
|
---|---|
(72) Inventors : |
|
(73) Owners : |
|
(71) Applicants : |
|
(74) Agent: | SMART & BIGGAR LP |
(74) Associate agent: | |
(45) Issued: | 1986-12-02 |
(22) Filed Date: | 1983-11-24 |
Availability of licence: | N/A |
Dedicated to the Public: | N/A |
(25) Language of filing: | English |
Patent Cooperation Treaty (PCT): | No |
---|
(30) Application Priority Data: | None |
---|
ABSTRACT
The invention relates to contraceptive vaginal tablets and to
a process for preparing them. The tablets of the invention have the
following composition: 0.2 to 3 parts by weight of boric acid, 10 to 20
parts by weight of tartaric acid, 1 to 2 parts by weight of vitamin K3-
sodium bisulfite adduct, 0.8 to 1.2 parts by weight of polyvinyl pyrrolidone,
2 to 5 parts by weight of magnesium stearate, 8 to 12 parts by weight of
carboxymethyl cellulose, 8 to 12 parts by weight of lactose and 50 to 65
parts by weight of microcrystalline cellulose. The vaginal tablets contain
preferably 5 to 10 mg of vitamin K3-sodium bisulfite adduct and have a
total weight of 500 mg. The tablets are prepared preferably in such a way
that the boric acid, the tartaric acid and the vitamin K3-sodium bisulfite
adduct, as well as the polyvinyl pyrrolidone, the magnesium stearate, the
carboxymethyl cellulose, the lactose and the microcrystalline cellulose are
homogenized separately to powder mixtures and thereafter the powder mixtures
are mixed and pressed to form tablets. The tablets should be wetted and
inserted into the back-vaginal fornix 10 minutes before the coitus.
Note: Claims are shown in the official language in which they were submitted.
Note: Descriptions are shown in the official language in which they were submitted.
Sorry, the representative drawing for patent document number 1214725 was not found.
2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.
Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.
For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee and Payment History should be consulted.
Description | Date |
---|---|
Inactive: Expired (old Act Patent) latest possible expiry date | 2003-12-02 |
Grant by Issuance | 1986-12-02 |
There is no abandonment history.
Note: Records showing the ownership history in alphabetical order.
Current Owners on Record |
---|
KOVACS, ANDRAS |
SZEBENI, RUDOLF |
KOSZEGI, BELA |
Past Owners on Record |
---|
ANDRAS KOVACS |
BELA KOSZEGI |
RUDOLF SZEBENI |